What are the side effects of fibrate therapy for treating elevated triglycerides?

Side Effects of Fibrate Therapy for Elevated Triglycerides

Fibrates are generally well-tolerated with the most common side effects being gastrointestinal upset, increases in serum creatinine (15-20%), and elevated liver transaminases, while serious complications like myopathy and rhabdomyolysis are rare but significantly increased when combined with statins or used in renal insufficiency.

Common Side Effects

Renal Effects

• Increases in plasma creatinine of 15-20% are common in fibrate-treated patients 1
• More significant increases occur in patients with underlying renal disease 1
• Fenofibrate is contraindicated when eGFR <30 mL/min/1.73 m² 2
• In patients with renal insufficiency (creatinine clearance 20-100 mL/min), fibrates should be initiated at the lowest available dose and increased only after re-evaluation of renal function and lipid parameters 1

Gastrointestinal Effects

• Gastrointestinal upset can occur 3
• Increased predisposition to cholelithiasis (gallstones) 3

Hepatic Effects

• Elevated liver transaminases can occur but are much less common than with statins 3
• Liver function tests should be monitored at baseline and periodically during treatment 4

Metabolic Effects

• Fenofibrate therapy results in elevations in serum homocysteine levels of uncertain clinical significance 1

Serious but Rare Side Effects

Myopathy and Rhabdomyolysis

The risk of myopathy and possible rhabdomyolysis is markedly increased when fibrates are combined with statins or used in the presence of renal insufficiency 3. Key points:

• Elevated creatine kinase can occur but is much less common than with statins 3
• Gemfibrozil should NOT be used in combination with a statin due to significantly higher risk of myopathy 1, 4
• Fenofibrate has less influence on statin pharmacokinetics compared to gemfibrozil and is safer for combination therapy 5
• The concurrent use of statins and fibrates raises the risk for rhabdomyolysis, and this combination should not be used in CKD 2

Other Serious Effects

• Skin reactions (22.8% of reported adverse events in French pharmacovigilance data) 6
• Blood disturbances and hemorrhage (9.8%), particularly interactions with coumarin derivatives (5.8%) 6
• Nervous system disorders, psychic disturbances, and libido changes (approximately 6% each) 6

Monitoring Requirements

Based on guideline recommendations 1, 4:

1. Baseline assessment:

   • Creatinine and creatinine clearance
   • Liver transaminases (ALT, AST)
   • Creatine kinase (CK)
   • Lipid profile

2. Follow-up monitoring:

   • Renal function and lipid parameters before any dose increase in patients with renal insufficiency
   • Liver transaminases periodically during treatment
   • Creatine kinase if muscle symptoms develop

Critical Clinical Pitfalls

Combination Therapy Risks

The most important safety consideration is avoiding gemfibrozil-statin combinations 1. If combination therapy is needed:

• Use fenofibrate rather than gemfibrozil with statins
• Monitor closely for muscle symptoms
• Check CK levels at baseline and if symptoms develop

Renal Insufficiency

• Fibrates are associated with increased risk of hospitalization due to creatinine elevation, with excess risk magnified in patients with CKD 2
• Dose adjustment is mandatory in renal impairment
• Fenofibrate is absolutely contraindicated when eGFR <30 mL/min/1.73 m² 2

Special Populations

In patients with diabetes or glucose intolerance, initiate therapy at 500-1000 mg/day and monitor glycemic control 1

Overall Safety Profile

Real-world data from a lipid clinic cohort with mean follow-up of 5.3 years showed that only 4.3% of patients experienced adverse effects (elevation of liver enzymes in 3, myalgia in 2, insomnia in 1, malaise in 1, and skin rash in 1 patient), with no cases of rhabdomyolysis or myopathy 7. Recovery from side effects is generally good in 80.9% of cases 6.